Syndax Pharmaceuticals trial advances to stage 2

Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) announced that patients in the ENCORE 601 non-small cell lung cancer trial will advance to the second stage of the Phase 2 trial. Shares of the biopharmaceutical leaped $4.19 to close at $13.58.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.